Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Government Forms Committee to Review Pharmaceutical Marketing Practices
    27 October 2026

    Government Forms Committee to Review Pharmaceutical Marketing Practices

    The Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers has constituted a committee to review the existing regulatory framework governing pharmaceutical marketing practices and recommend measures to strengthen monitoring, oversight and enforcement across the sector. The committee will examine issues relating to unethical pharmaceutical marketing practices and recommend measures to improve transparency, accountability and compliance. It is required to submit its recommendations within two months from the date of its first meeting.

  • Mankind Pharma Net Profit Jumps 38% to ₹716 Crore, Revenue Rises 17%
    27 October 2026
    Mankind Pharma Net Profit Jumps 38% to ₹716 Crore, Revenue Rises 17%
    Mankind Pharma Limited reported strong financial performance for the second quarter of FY2026–27, with consolidated revenue from operations rising 17.3% year-on-year to ₹4,338 crore, compared with ₹3,697 crore in the corresponding quarter last year.
  • Cipla Revenue Declines 2% to ₹7,404 Crore, Net Profit Falls to ₹878 Crore
    27 October 2026

    Cipla Revenue Declines 2% to ₹7,404 Crore, Net Profit Falls to ₹878 Crore

    Cipla Limited on Tuesday announced its unaudited consolidated financial results for the second quarter of FY2026–27, reporting operating revenue of ₹7,404 crore, down 2% year-on-year from ₹7,589 crore in the corresponding quarter last year.
  • J&J Reports 77% Tumour Response with RYBREVANT FASPRO-Based Combination in Advanced Head and Neck Cancer
    26 October 2026
    J&J Reports 77% Tumour Response with RYBREVANT FASPRO-Based Combination in Advanced Head and Neck Cancer
    Johnson & Johnson has reported a confirmed overall response rate (ORR) of 77% with a combination regimen containing RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) in previously untreated patients with recurrent or metastatic head and neck squamous cell carcinoma
  • CDSCO’s September NSQ Alert Flags Multiple Mounjaro KwikPen Batches, Other Drug Quality Failures
    26 October 2026
    CDSCO’s September NSQ Alert Flags Multiple Mounjaro KwikPen Batches, Other Drug Quality Failures
    The Central Drugs Standard Control Organization (CDSCO), in its September 2026 Not of Standard Quality (NSQ) alert, has listed multiple batches of Eli Lilly’s Mounjaro KwikPen against reported assay, sterility and related-substances testing failures.
  • A New Peptide Strategy Shows Promise in Reducing Alzheimer’s-Linked Amyloid in Mice
    23 October 2026
    A New Peptide Strategy Shows Promise in Reducing Alzheimer’s-Linked Amyloid in Mice

    Researchers have identified a synthetic peptide that may offer a new approach to studying and modulating the biological processes associated with Alzheimer’s disease. The compound, known as P33, reduced amyloid-beta (Aβ) levels and amyloid plaque burden in mice engineered to develop Alzheimer’s-like pathology, according to a study published in Bioorganic Chemistry.

  • FDA Clears First Generic Weekly Hormone Patch, Expanding Menopause Treatment Options
    23 October 2026
    FDA Clears First Generic Weekly Hormone Patch, Expanding Menopause Treatment Options
    The U.S. Food and Drug Administration (FDA) has approved the first generic version of Climara Pro, a combination hormone therapy patch designed for women with an intact uterus. The approval introduces another treatment option for managing menopause-related symptoms and helping prevent postmenopausal osteoporosis.
  • Allergan Aesthetics Highlights New Clinical Evidence and Multimodal Treatment Approach at AMWC Dubai 2026
    22 October 2026
    Allergan Aesthetics Highlights New Clinical Evidence and Multimodal Treatment Approach at AMWC Dubai 2026
    Allergan Aesthetics, a subsidiary of AbbVie, is showcasing new and long-term clinical evidence supporting its aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Dubai, held from October 21 to 23, 2026.
  • Too much RNA can starve cells of energy, study finds
    22 October 2026
    Too much RNA can starve cells of energy, study finds
    A new study from researchers at the Texas A&M College of Veterinary Medicine and Biomedical Sciences (VMBS) has uncovered a previously unknown consequence of viral infection: too much RNA inside a cell can disrupt its ability to produce energy.
  • Dr. Reddy’s Receives DCGI Approval for Zytorvi
    21 October 2026
    Dr. Reddy’s Receives DCGI Approval for Zytorvi
    Dr. Reddys Laboratories Ltd announced that the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), has approved Zytorvi® (toripalimab) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
Subscribe to Pharma News